Siren L.L.C. Sells 42,267 Shares of Trevi Therapeutics, Inc. $TRVI

Key Points

• Siren L.L.C. reduced its stake in Trevi Therapeutics by 1.5%, selling 42,267 shares, and now holds 2,863,793 shares, representing approximately 1.0% of its investment portfolio.
• The stock of Trevi Therapeutics opened at $9.62 with a market cap of $1.17 billion, experiencing a 1-year low of $2.36 and a high of $9.81.
• Analysts have mixed ratings on Trevi Therapeutics with a general consensus of "Buy" and a price target averaging $21.75, while Raymond James recently lowered their target from $29.00 to $27.00.

Siren L.L.C. lessened its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 1.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,863,793 shares of the company's stock after selling 42,267 shares during the quarter. Trevi Therapeutics accounts for approximately 1.0% of Siren L.L.C.'s investment portfolio, making the stock its 24th biggest holding. Siren L.L.C. owned 2.87% of Trevi Therapeutics worth $18,013,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in Trevi Therapeutics during the fourth quarter worth $49,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics in the fourth quarter valued at about $58,000. Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics in the fourth quarter valued at about $66,000. ProShare Advisors LLC grew its stake in Trevi Therapeutics by 86.4% during the fourth quarter. ProShare Advisors LLC now owns 20,685 shares of the company's stock worth $85,000 after buying an additional 9,589 shares in the last quarter. Finally, Diversified Trust Co acquired a new stake in Trevi Therapeutics during the first quarter worth about $94,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $9.62 on Thursday. The firm has a market cap of $1.17 billion, a P/E ratio of -22.90 and a beta of 0.71. The stock has a 50 day simple moving average of $7.24 and a two-hundred day simple moving average of $6.45. Trevi Therapeutics, Inc. has a 1 year low of $2.36 and a 1 year high of $9.81.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TRVI. Raymond James Financial dropped their target price on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating for the company in a report on Friday, August 8th. HC Wainwright started coverage on shares of Trevi Therapeutics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price target on the stock. Wall Street Zen lowered shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Finally, Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday, June 2nd. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Trevi Therapeutics has a consensus rating of "Buy" and a consensus price target of $21.75.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.